Interpace appoints Vijay Aggarwal to Board, replacing Eric Lev effective Feb 1, 2022

INTERPACE BIOSCIENCES, INC.

Eric B. Lev resigns as director effective Feb 1, 2022; no disagreement with the Company.
Vijay Aggarwal appointed to Board effective Feb 1, 2022 as Class I director.
Aggarwal will Chair Regulatory Compliance Committee and serve on Nominating & Corporate Governance Committee.
Compensation: $50k annual director fee ($40k base + $10k committee chair) plus option for 28k shares.
Aggarwal has 30+ years in diagnostics/pharma; previously CEO of Vaxigenix, President of Aureon Labs.

item 1.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Vijay Aggarwal

Director

IDXG · INTERPACE BIOSCIENCES, INC.

Effective: 2022-02-01
Filed: January 27, 2022, 6:59 PM ET

Dr. Vijay Aggarwal as a director to replace Mr. Lev on the Company's Board, effective February 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Vijay Aggarwal was appointed as Director at INTERPACE BIOSCIENCES, INC..

Action: appointed
Role: Director

Exact text from the filing

Dr. Vijay Aggarwal as a director to replace Mr. Lev on the Company's Board, effective February 1, 2022.

View on SEC.gov

INTERPACE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-22-002401

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.